Jack Bendheim Sells 5,280 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 5,280 shares of Phibro Animal Health stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $51.66, for a total transaction of $272,764.80. Following the transaction, the chief executive officer directly owned 90,920 shares in the company, valued at approximately $4,696,927.20. This represents a 5.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Jack Bendheim also recently made the following trade(s):

• On Thursday, March 19th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.52, for a total value of $369,740.80.
• On Wednesday, March 18th, Jack Bendheim sold 10,560 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.68, for a total value of $556,300.80.
• On Friday, March 13th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $48.91, for a total value of $258,244.80.
• On Thursday, February 26th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $53.73, for a total value of $378,259.20.
• On Tuesday, February 24th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.37, for a total value of $361,644.80.
• On Friday, February 20th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.42, for a total value of $361,996.80.
• On Wednesday, February 18th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.40, for a total value of $361,856.00.
• On Friday, February 13th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.96, for a total transaction of $365,798.40.
• On Wednesday, February 11th, Jack Bendheim sold 14,184 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.62, for a total transaction of $732,178.08.
• On Tuesday, February 10th, Jack Bendheim sold 58,014 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.81, for a total transaction of $3,005,705.34.

Phibro Animal Health Stock Performance

PAHC stock traded up $0.15 during mid-day trading on Thursday, hitting $52.38. The company had a trading volume of 347,486 shares, compared to its average volume of 255,491. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.22 and a current ratio of 3.05. The firm has a market cap of $2.12 billion, a PE ratio of 23.28, a price-to-earnings-growth ratio of 0.80 and a beta of 0.74. Phibro Animal Health Corporation has a 12 month low of $16.16 and a 12 month high of $56.30. The stock’s fifty day moving average price is $47.34 and its two-hundred day moving average price is $42.65.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.18. The firm had revenue of $373.91 million during the quarter, compared to the consensus estimate of $355.64 million. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. On average, analysts forecast that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Wednesday, March 4th will be paid a $0.12 dividend. The ex-dividend date is Wednesday, March 4th. This represents a $0.48 annualized dividend and a dividend yield of 0.9%. Phibro Animal Health’s payout ratio is presently 21.33%.

Hedge Funds Weigh In On Phibro Animal Health

Hedge funds have recently made changes to their positions in the stock. Penserra Capital Management LLC purchased a new stake in Phibro Animal Health during the 3rd quarter worth about $519,000. Capricorn Fund Managers Ltd purchased a new position in Phibro Animal Health during the 3rd quarter valued at about $10,233,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Phibro Animal Health during the third quarter valued at about $8,931,000. Citigroup Inc. lifted its holdings in shares of Phibro Animal Health by 112.3% in the third quarter. Citigroup Inc. now owns 54,941 shares of the company’s stock worth $2,223,000 after buying an additional 29,066 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in shares of Phibro Animal Health in the second quarter worth about $813,000. 99.34% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on PAHC. Zacks Research upgraded Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 11th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. Finally, Morgan Stanley set a $49.00 target price on shares of Phibro Animal Health in a research note on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Phibro Animal Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.50.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.